Discovery PhysChem at UCB AKAS and Beyond
Christine Prosser
It is a well-documented fact that as the R&D spend has increased year on year
the number of new drugs reaching the market has decreased often as a result of
undesirable properties, unrelated to potency or selectivity, which emerge late
in the discovery process. In an attempt to reduce this costly late phase
attrition pharmaceutical companies are introducing ADMET investigations in
parallel with traditional biological assays as an early warning filter and to
drive medicinal chemistry.
In the last year the acquisition of Celltech by UCB Pharma has created a
major European based bio-pharma entity. This talk will highlight how the
physical chemistry team at our Slough UK site is dedicated to developing robotic
screens and now provides a cascade of physicochemical profiling assays for early
discovery support.
| 
for
Physical Chemists by Physical Chemists
